Prudential Financial Inc Immunovant, Inc. Transaction History

Prudential Financial Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$30.27 - $43.79 $768,282 - $1.11 Million	-25,381 Reduced 41.79%	35,349 $1.14 Million
Q4 2023 Feb 13, 2024	BUY	$31.31 - $44.19 $1.12 Million - $1.59 Million	35,890 Added 144.48%	60,730 $2.56 Million
Q3 2023 Nov 13, 2023	SELL	$18.55 - $39.96 $897,820 - $1.93 Million	-48,400 Reduced 66.08%	24,840 $953,000
Q2 2023 Aug 11, 2023	SELL	$14.2 - $23.75 $715,538 - $1.2 Million	-50,390 Reduced 40.76%	73,240 $1.39 Million
Q1 2023 May 12, 2023	BUY	$15.27 - $19.72 $105,363 - $136,068	6,900 Added 5.91%	123,630 $1.92 Million
Q4 2022 Feb 14, 2023	BUY	$6.59 - $17.75 $2,306 - $6,212	350 Added 0.3%	116,730 $0
Q3 2022 Nov 04, 2022	BUY	$3.93 - $6.37 $457,373 - $741,340	116,380 New	116,380 $650,000
Q2 2021 Aug 16, 2021	SELL	$9.4 - $16.85 $170,271 - $305,220	-18,114 Closed	0 $0
Q1 2021 May 12, 2021	BUY	$13.08 - $49.6 $175,742 - $666,425	13,436 Added 287.22%	18,114 $290,000
Q4 2020 Feb 16, 2021	BUY	$36.36 - $52.71 $170,092 - $246,577	4,678 New	4,678 $217,000

211

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Prudential Financial Inc with notifications on news.